- The Global Erectile Dysfunction Drugs Market was valued at USD 2319.8 Million in 2021
- It is anticipated to reach USD 4079.9 Million by 2028
- A CAGR of 8.4% is anticipated over the forecast period
Sildenafil (Viagra), vardenafil (Levitra, Staxyn), tadalafil (Cialis), and avanafil (Stendra) are oral medications that reverse erectile dysfunction by increasing the effects of nitric oxide, a natural chemical your body produces, that relaxes the muscles in the penis. Erectile dysfunction is generally an age-related condition but can also be caused by psychological factors. Cardiovascular diseases such as high blood pressure, blockage of blood vessels, diabetes, hormonal insufficiency, chronic kidney disease, multiple sclerosis, male genital, bladder, and abdominal injuries, and neurological problems are common factors that can cause erectile dysfunction.
The Covid-19 pandemic has negatively impacted the growth of the global erectile dysfunction drugs market. Emmanuel A. The research, led by Giannini, MD, professor of endocrinology and medical sexology at the University of Rome Tor Vergata in Rome, Italy, was published in March 2020 in the journal Andrology. Covid-19 is five times more common in men with ED. The estimated risk of developing ED was 5.66 times higher among men with a history of Covid-19. Thus, the Covid-19 pandemic has had a significant impact on the erectile dysfunction drugs market. However, Due to the increasing prevalence of erectile dysfunction during the Covid-19 pandemic, the global erectile dysfunction drugs market is expected to multiply during the forecast period.
Some of the key players for global Erectile Dysfunction Drugs Market are-
The global erectile dysfunction drugs market is segmented on the product, distribution channel and region & country level. Based on product, the global erectile dysfunction drugs market is segmented into cialis, stendra/spedra, staxyn/levitra, viagra, and others. The viagra segment is the highest revenue generator, and many companies are taking advantage of this market opportunity by engaging in strategic initiatives such as research collaborations, partnerships, and agreements. For example, in January 2020, Pfizer, Inc., and Digital Men's Clinic Roman signed a supply agreement to provide a generic version of Viagra to Roman members. This supply agreement is likely to enhance the segment's growth prospects.
The other segment of the erectile dysfunction drugs market is anticipated to experience lucrative growth during the forecast period due to the wide range of applications and the availability of ED medications, such as Helleva (lodenafil carbonate), Mvix (mirodenafil), and others, which are also used to treat adult patients with erectile dysfunction. The increasing approval of over-the-counter ED products provides easy access to ED patients. For instance, in February 2022, Adamed became the first Polish company to receive marketing authorization approval for Tadalafil MAXON from prescription to over-the-counter (OTC) status. Thus, the introduction of such products in the market is likely to boost the use of ED drugs.
By distribution channel, the global erectile dysfunction drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment is predicted to be the fastest growing sector due to the increasing pool of patients caused by heightened awareness and patient education.
Geographically, North America is expected to capture a major share in the global erectile dysfunction drugs market within the forecast period due to the increasing number of ED cases, rising geriatric population, and higher consumption of recreational drugs in this region. An increasing number of ED cases is driving the growth of the market. For instance; according to the Cleveland Clinic, on October 14th, 2019; it is estimated that one in 10 adult men suffer from ED on a chronic basis. In addition, the rising geriatric population is another factor supplementing the market growth in this region. For example; according to Rural Health Information Hub, on April 6th, 2019; there were 46 million people aged 65 in the US. The number of geriatric populations is projected to double to 90 million by 2050.
The Asia Pacific is the fastest-growing region in the global erectile dysfunction drugs market due to increasing research facilities, rising geriatric population, and the presence of low-cost skilled labor in this region. For instance; according to ageing Asia, in 2019, they were 139 million people aged 65 in India.
One of the major factors driving the growth of the erectile dysfunction drug market is the increasing number of erectile dysfunctions (ED). Due to the increase in adopting a poor lifestyle, diabetes, obesity, and cardiovascular diseases are on the rise, leading to problems like ED as people age. The current lifestyle of young people in many emerging countries is very stressful, resulting in increased consumption of alcohol, smoking, and fast food or prepared food. Due to these factors, overall health and fitness are compromised which increases the chances of ED. Moreover, as the elderly population increases, so does the number of ED patients, which is a significant driver of the global erectile dysfunction drugs market throughout the forecast period. For instance; according to Johns Hopkins Medicine, by 2025, the prevalence of ED is estimated to be approximately 322 million worldwide.
In addition, the rising geriatric population is also supplementing the growth of the erectile dysfunction drugs market. An erection mainly involves blood vessels and the most common causes of erectile dysfunction in older men are conditions that block blood flow to the penis. These include hardening of the arteries and diabetes. Some parts of the world, such as China and Japan, are facing a unique crisis. The population of senior citizens is increasing rapidly in these countries. This is a serious one; the healthcare industry itself is indicative as demand for the products will be high across all healthcare markets in these sectors. Consequently, the global erectile dysfunction drug market is also expected to benefit from this trend. For instance; according to The United Nation, in 2019, they were 703 million people in the world aged 65 years. By 2050, the geriatric population is projected to double to 1.5 billion.
Moreover, the growing number of chronic diseases is also augmenting the erectile dysfunction drugs market growth. Erectile dysfunction is mainly caused by chronic diseases caused by a sedentary lifestyle such as cardiovascular disease, diabetes, obesity, and high blood pressure. For example; according to the Center for Disease Control Gov., on September 17th, 2020; 51.8% of US adults had at least one chronic condition, and 27.2% had multiple chronic conditions. Prevalence of chronic diseases increases the chances of erectile dysfunction in men, thereby increasing the market for erectile dysfunction drugs.
- On January 18th, 2022; Petros Pharmaceuticals, Inc., a leading provider of therapeutics for men's health, initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil). The results of these studies lead to potential over-the-counter (OTC) status for STENDRA (avanafil) in the U.S. It is part of a more comprehensive data package the company plans to submit to the Food and Drug Administration (FDA).
|2016 - 2021
|2022 - 2029
|Market Size in 2021:
|USD 2319.8 Million
|Base year considered
|Forecast Period CAGR %:
|Market Size Expected in 2028:
|USD 4079.9 Million
|Tables, Charts & Figures:
|Erectile Dysfunction Drugs Players
|Pfizer, Inc., Meda Pharmaceuticals, Inc., Dong-A ST Co., Ltd., SK Chemicals, Eli Lilly & Company, Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd. , Apricus Biosciences, Inc., Vivus, Inc., Teva Pharmaceutical Industries Ltd., Futura Medical plc,Apricus Biosciences Inc., GlaxoSmithKline PLC, Petros Pharmaceutical, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, And others.
|By Drug, By Distribution Channel
|North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us email@example.comJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®